AQUA-COMMS
25.3.2022 09:02:06 CET | Business Wire | Press release
Aqua Comms , a leading provider of global subsea connectivity services today announced the successful launch of CeltixConnect-2 (CC-2) and North Sea Connect (NSC) as part of its ownership of the Havhingsten cable system.
CC-2 is Aqua Comms’ second unrepeated system between the key data hubs of Ireland and the UK, with diverse landings into the Isle of Man (IOM). Together with CC-1 the new system brings resilient, high fibre count, capacity connectivity between these key hubs for the Carrier, Cloud and Content markets.
NSC offers a completely new route connecting the UK and the Nordics and is a repeated cable system connecting the Stellium Data Centre at D9’s SeaEdge-1 in Newcastle, UK and Blaabjerg, Denmark which also hosts Aqua Comms’ AEC-2 Trans-Atlantic cable system.
CC-2 and NSC also combine to provide regional connectivity to Aqua Comms’ AEC-1 and AEC-2 Trans-Atlantic cables ensuring resilience and diversity between the US, Ireland, the UK and the Nordics.
Chris Bayly, CCO of Aqua Comms, commented, “The addition of these two new regional systems mark an important milestone for Aqua Comms. By connecting Ireland, the UK and the Nordics, Aqua Comms is bringing its industry-leading connectivity services to these key growth markets whilst also enhancing its Trans-Atlantic footprint and connectivity between the US and Europe”
Bayly added, “This demonstrates our continued investment in delivering services to underserved markets and I’m excited to see this continue with the rollout of AEC-3 and EMIC-1”
About Aqua Comms
Aqua Comms is a leading provider of global subsea connectivity services delivered through an extensive portfolio of owned and operated subsea systems. Aqua Comms offers connectivity networking solutions including managed capacity services, spectrum and dark fibre to the global content, cloud and carrier markets.
To learn more about Aqua Comms and its portfolio of connectivity networking solutions visit www.aquacomms.com .
In April 2021, Aqua Comms DAC was acquired by Digital 9 Infrastructure plc (D9), an LSE listed investment trust managed by Triple Point Investment Management LLP.
D9 is a digital infrastructure investment trust that has raised over US$ 1.1 billion since its IPO in March 2021, investing US$ 650 million into data centres and fibre networks. Its team has over US$ 250 billion transactional and operational experience in digital infrastructure. The number 9 in Digital 9 Infrastructure comes from the UN Sustainable Development Goal number 9, which focuses the fund on investments that bridge the digital divide by increasing connectivity globally and that improve the environmental sustainability of digital infrastructure.
To learn more about D9 visit www. https://www.d9infrastructure.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom